Abstract
A screening procedure which permits identification of compounds based on their activities against specific biological targets directly in a living organism, Saccharomyces cerevisiae, has been established as part of our new drug discovery programme. Use of this assay has provided the first direct evidence that TOP1 and RAD52 proteins are involved in the mode of action of bisdioxopiperazine ICRF compounds, which thus express a mode of action quite distinctive from the other known TOP2 inhibitors evaluated. The functional assay is based on a comparison of pairs of yeast differing in their phenotypes by specific traits: the expression or lack of expression of ectopic human DNA topoisomerase I, with or without that of the RAD52 gene. Amongst a series of anticancer agents, inhibitors of topoisomerase I (camptothecin) were identified as such in yeast expressing human topoisomerase I, whilst the presence or absence of RAD52 protein permitted the discrimination of compounds generating double-stranded DNA breaks, either directly (bleomycin) or involving DNA adduct formation (cisplatin), or indirectly with DNA damage mediated via inhibition of the topoisomerase II enzyme (etoposide). Notably, however, both the RAD52 protein and the lack of TOP1 enzyme appeared implicated in the cytotoxic activities of the series of bisdioxopiperazine ICRF compounds tested. This functional assay in a living organism therefore appears to provide a valuable tool for probing distinctive and specific mode(s) of action of diverse anticancer agents.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abe, H, Wada, M, Kohno, K & Kuwano, M (1994) Altered drug sensitivities to anticancer agents in radiation-sensitive DNA repair deficient yeast mutants. Anticancer Res 14: 1807–1810.
Andoh, T & Ishida, R (1998) Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1400: 155–171.
Ausubel, FM, Brent, R, Kingston, RE, More, DD, Seidman, JG, Smith, JA & Struhl, K (1995). Current Protocols in Molecular Biology. Current Protocols: Boston
Barret, J-M & Hill, BT (1998) DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. Anticancer Drugs 9: 105–123.
Bennett, CB, Snipe, JR & Resnick, MA (1997) Persistent double-strand break destabilizes human DNA in yeast and can lead to G2 arrest and lethality. Cancer Res 57: 1970–1980.
Bjornsti, MA, Benedetti, P, Viglianti, GA & Wang, JC (1989) Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity to the antitumor drug camptothecin. Cancer Res 49: 6318–6323.
Chaney, SG & Sancar, A (1996) DNA repair, enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88: 1346–1360.
Chen, AY & Liu, LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191–218.
Corbett, AH & Osheroff, N (1993) When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplasic drugs. Chem Res Toxicol 6: 585–597.
Creighton, AM (1971). Piperazine derivatives. UK Patent 1234935.
Creighton, AM (1974). 3,5-Dioxopiperazine derivatives. UK Patent 1374979.
DeVita, VT Jr, Hellman, S & Rosenberg, SA (1993). Cancer, Principles and Practice of Oncology, 4th edn. JB Lippincott, Philadelphia
Eng, WK, Faucette, L, Johnson, RK & Sternglanz, R (1988) Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34: 755–760.
Friedberg, EC, Siede, W & Cooper, AJ (1991). Responses to DNA damage in yeast. In: The Molecular and Cellular Biology of the Yeast Saccharomyces, Broach JR, Pringle JR and Jones EW (eds), pp. 147–192, Cold Spring Harbor Laboratory Press: Cold Spring Harbor
Hasinoff, BB, Kushchak, TI, Yalowich, JC & Creighton, AM (1995) A qsar study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50: 953–958.
Hasinoff, BB, Reinders, FX & Clarck, V (1991) The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. Drug Metab Disposition 19: 74–80.
Hays, SL, Firmenich, AA & Berg, P (1995) Complex formation in yeast double-strand breaks repair: participation of rad51, RAD52, rad55, and rad57 proteins. Proc Natl Acad Sci USA 92: 6925–6929.
Ishida, R, Hamatake, M, Wasserman, RA, Nitiss, JL, Wang, JC & Andoh, T (1995) DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55: 2299–2303.
Johnson, SA, Harper, P, Hortobagyi, GN & Pouillart, P (1996) Vinorelbine: an overview. Cancer Treat Rev 22: 127–142.
Kingsbury, WD, Boehm, JC, Jakas, DR, Holden, KG, Hecht, SM, Gallagher, G, Caranfa, MJ, McCabe, FL, Faucette, LF, Johnson, RK & Hertzberg, RP (1991) Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98–107.
Milne, GT & Weaver, DT (1993) Dominant negative alleles of RAD52 reveals a DNA repair/recombination complex including Rad51 and RAD52. Genes Dev 7: 1755–1765.
Nitiss, J & Wang, JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85: 7501–7505.
Osheroff, N (1989) Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmac Ther 41: 223–241.
Pinedo, HM, Longo, DL & Chabner, BA (1997). Cancer Chemotherapy and Biological Response Modifiers Annual 17. Elsevier: Amsterdam
Pommier, Y, Tanizawa, A & Kohn, KW (1994) Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol 29B: 73–92.
Ramotar, D & Masson, JY (1996) Saccharomyces cerevisiae DNA repair processes: an update. Mol Cell Biochem 158: 65–75.
Roca, J, Ishida, R, Berger, JM, Andoh, T & Wang, JC (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91: 1781–1785.
Sehested, M & Jensen, PB (1996) Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51: 879–886.
Sehested, M, Buhl, P, Sorensen, BS, Holm, B, Friche, E & Demant, EJF (1993) Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46: 389–393.
Shen, DW, Akiyama, SI, Schoenlein, P, Pastan, I & Gottesman, MM (1995) Characterisation of high-level cisplatin-resistant cell lines established from cross-resistance and protein changes. Br J Cancer 71: 676–683.
Subramanian, D, Rosenstein, BS & Muller, MT (1998) Ultraviolet-induced DNA damage stimulates topoisomerase I–DNA complex formation in vivo: possible relationship with DNA repair. Cancer Res 58: 976–984.
Thielmann, HW, Popanda, O, Gersbach, H & Gilberg, F (1993) Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis 14: 2341–2351.
Utsugi, T, Shibata, J, Sugimoto, Y, Aoyagi, K, Wierzba, K, Kobunai, T, Terada, T, Oh-Hara, T, Tsuro, T & Yamada, Y (1996) Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res 56: 2809–2814.
van Hille, B & Hill, BT (1998) Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterisation of topoisomerase II-targeting antitumor agents. Cancer Chemother Pharmacol 42: 345–356.
Van Rosmalen, A, Cullinane, C, Cutts, SM & Phillips Don, R (1995) Stability of adriamycin-induced DNA adducts and intrastrand crosslinks. Nucleic Acids Res 23: 42–50.
Wall, ME, Wani, MC, Cooke, CE, Palmer, KH, McPhail, AT & Slim, GA (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888–3890.
Wang, JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665–697.
Wood, RD (1996) DNA repair in eukaryotes. Annu Rev Biochem 65: 135–167.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hille, B., Clerc, X., Creighton, A. et al. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. Br J Cancer 81, 800–807 (1999). https://doi.org/10.1038/sj.bjc.6690767
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690767